Edward B. Garon, MD
The combination of pegilodecakin (AM0010) and anti–PD-1 therapy demonstrated durable responses in patients with non–small cell lung cancer (NSCLC), according to findings presented at the 2018 ASCO Annual Meeting.
In the phase I study, pegilodecakin, which is a long-acting PEGylated Interleukin (IL)-10, was administered subcutaneously at 10 to 20 µg/kg daily. Five patients received pembrolizumab (Keytruda) at 2 mg/kg every 3 weeks and 29 received nivolumab (Opdivo) at 3 mg/kg every 2 weeks.
... to read the full story